Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Three risk factors—high blood pressure, atrial fibrillation, and smoking—are more likely to cause severe strokes, meaning ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...